Steve Weitman - Publications, H-index & Citations

Steve Weitman

university of texas system

23H指数

60论文数

3.0K被引数

收录论文 9

发表时间

A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier

PHARMACEUTICS

IF5.5

2018-05-19

OAAI

Takabe, Hiroyuki; Warnken, Zachary N.; Zhang, Yajie; Davis, Daniel A.; Smyth, Hugh D. C.; Kuhn, John G.; Weitman, Steve; Williams, Robert O., III

An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011

JOURNAL OF GERIATRIC ONCOLOGY

IF2.7

2014-01-01

OAAI

Rowe, Julie; Patel, Sukeshi; Mazo-Canola, Marcela; Parra, Alberto; Goros, Martin; Michalek, Joel; Kelly, Kevin; Weitman, Steve; Karnad, Anand

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response 阿仑单抗的群体药代动力学-药效学 (Campath®) 慢性淋巴细胞白血病患者及其与治疗反应的联系

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2007-05-16

110

OAAI

Mould, D. R.; Baumann, A.; Kuhlmann, J.; Keating, M. J.; Weitman, S.; Hillmen, P.; Brettman, L. R.; Reif, S.; Bonate, P. L.

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2006-10-01

255

PREAI

Bonate, Peter L.; Arthaud, Larry; Cantrell, William R., Jr.; Stephenson, Katherine; Secrist, John A., III; Weitman, Steve

Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors

CLINICAL CANCER RESEARCH

IF10.2

2006-09-01

OAAI

Mita, Alain C.; Hammond, Lisa A.; Bonate, Peter L.; Weiss, Geoffrey; McCreery, Heather; Syed, Samira; Garrison, Mitchell; Chu, Quincy S. C.; DeBono, Johann S.; Jones, Christopher B.; Weitman, Steve; Rowinsky, Eric K.

Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors

CLINICAL CANCER RESEARCH

IF10.2

2005-11-08

PREAI

Cunningham, C; Appleman, LJ; Kirvan-Visovatti, M; Ryan, DP; Regan, E; Vukelja, S; Bonate, PL; Ruvuna, F; Fram, RJ; Jekunen, A; Weitman, S; Hammond, LA; Eder, JP

A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors

CLINICAL CANCER RESEARCH

IF10.2

2005-11-08

OAAI

Ebbinghaus, S; Rubin, E; Hersh, E; Cranmer, LD; Bonate, PL; Fram, RJ; Jekunen, A; Weitman, S; Hammond, LA

Antitumor activity of a kinesin inhibitor

CANCER RESEARCH

IF16.6

2004-05-03

273

OAAI

Sakowicz, R; Finer, JT; Beraud, C; Crompton, A; Lewis, E; Fritsch, A; Lee, Y; Mak, J; Moody, R; Turincio, R; Chabala, JC; Gonzales, P; Roth, S; Weitman, S; Wood, KW

Biodegradable block copolymers for delivery of proteins and water-insoluble drugs 用于递送蛋白质和水不溶性药物的可生物降解的嵌段共聚物

JOURNAL OF CONTROLLED RELEASE

IF11.5

2001-05-01

602

PREAI

Zentner, GM; Rathi, R; Shih, C; McRea, JC; Seo, MH; Oh, H; Rhee, BG; Mestecky, J; Moldoveanu, Z; Morgan, M; Weitman, S

研究方向